Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 Monotherapy.

Clin Cancer Res · 2021 · PMC9401488 · PMID 34376536

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

marginal significanceno p-value reported

Early onset (both within 8 and 26 weeks after anti–PD-1 monotherapy initiation) irAEs that led to the use of high-dose GCC were associated with poorer post-irAE PFS in the MGH cohort (with statistical significance for 8-week landmark analysis and marginal significance for 26-week) and this was validated in the combined cohort ( Table 4 ).

also in 5,069 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.